IndustryCompany release

IQVIA lifts 2026 guidance after third-quarter revenue rises 8% to $4.43bn

🇺🇸 Iqvia Holdings Inc. (IQV) · Tue 27 Oct 2026

The contract research and analytics group reported $3.2bn in R&D Solutions net new bookings, while a review of inactive trials trimmed its contracted backlog by about $2.1bn.

IQVIA (NYSE:IQV) reported third-quarter 2026 results on 27 October, with revenue of $4,428 million and GAAP net income of $350 million. The company's headline release put revenue growth at 8%.

In its R&D Solutions segment, net new bookings reached $3.2 billion, a 15% rise on the headline figure. Contracted backlog for the segment stood at $32.6 billion at the end of the quarter. That figure reflects a reduction of roughly $2.1 billion arising from a review of inactive trials.

IQVIA raised its 2026 guidance for revenue, Adjusted EBITDA and adjusted earnings per share. The summary available does not give the new ranges, nor a breakdown of results by business segment beyond R&D Solutions.

The company also scheduled an Investor Day for 1 December 2026.

What it means for your team

  • The $3.2bn in R&D Solutions bookings and the raised guidance suggest continued demand for outsourced clinical development services, though the summary gives no detail on therapeutic areas or customer types.
  • The roughly $2.1bn backlog reduction from a review of inactive trials shows that reported backlog can include stalled studies; sponsors and vendors may want to consider how inactive projects are treated in their own pipeline and capacity planning.
  • Further detail on guidance ranges and segment performance should be available from IQVIA's full results materials and the 1 December Investor Day.

Company's press release (SEC filing): Iqvia Holdings Inc. ↗

Article written by VigiEye from the official source (Iqvia Holdings Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →